Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > News > Harmful bacteria play greater role in predicting outcomes of immune checkpoint blockade in melanoma
  • News

Harmful bacteria play greater role in predicting outcomes of immune checkpoint blockade in melanoma

  • 4 March 2022
  • Janet Fricker
gut microbiome and Abiraterone response in prostate cancer
Harmful bacteria play greater role in predicting outcomes of immune checkpoint blockade in melanoma
Total
15
Shares
15
0
0
0
0

Harmful gut bacteria may play a greater role than beneficial bacteria in determining efficacy of immune checkpoint blockade in melanoma patients. The study, published in Nature Medicine (28 February), found microbial signatures containing Lachnospiraceae species were connected to favourable anti-programmed cell death protein-1 (anti PD-1) clinical responses, while signatures containing Streptococcaceae species were connected to unfavourable responses.

The intestinal microbiome has emerged as a tumour-extrinsic predictive biomarker of immune checkpoint blockade efficacy. Administration of certain gut commensals has been shown to promote efficacy of anti-PD-1 in mice suggesting microbiota can affect immunotherapy outcomes. Furthermore, in two proof-of-concept trials, faecal microbiota transplanted from responders to non-responders overcame anti-PD-1 resistance in a third of melanoma patients. However, it has been unclear whether the microbiome exerts positive or negative effects on immune checkpoint blockade efficacy.

In the current collaboration, investigators from Oregon State University, the National Cancer Institute, the Frederick National Laboratory for Cancer Research and the University of Pittsburgh performed a meta-analysis of microbial sequencing data from four published independent cohorts from Chicago, Dallas, Houston and New York of anti-PD-1 treated melanoma patients, together with a new cohort. The new Pittsburgh cohort involved collecting stool samples from 94 anti-PD-1 treated patients with melanoma before treatment or within four months of starting anti-PD-1.

Using a statistical modelling technique, known as transkingdom network analysis, the team identified distinct microbial signatures associated with specific immune-related adverse events, profiles and outcomes. They also explored whether the machine learning model could be trained on one cohort and then used to predict anti-PD-1 responses in a second cohort.

Key findings included:

  • Overall 27 distinct microbiotypes were identified.
  • Meta-analysis and other bioinformatic analyses of the combined data show that bacteria associated with favourable response are confined within the Actinobacteria phylum and the Lachnospiraceae/ Ruminococcaceae families of Firmicutes.
  • Gram-negative bacteria were associated with an inflammatory host intestinal gene signature, increased blood neutrophil-to-lymphocyte ratios and unfavourable outcomes.
  • Favourable bacteria of the Lachnospiraceae family enhanced the immunostimulatory effects of anti-PD1 against cancer and self-antigens, while others dominated by Streptococcus spp induced organ pathology without enhancing immunity.
  • A year after treatment begins, the gut microbiota became a dominant factor in response to therapy, and then the microbes detracting from therapy played a larger role than the ones enhancing therapy.
  • Microbiotypes showed an unequal distribution across the five cohorts.
  • Machine learning trained by an individual cohort failed to predict response across the other cohorts, likely due to cohort heterogeneity and small size.

“Our findings shed new light on the highly complicated interaction between the gut microbiome and cancer immunotherapy response and set a course for future studies,” said Andrey Morgun, one of the investigators from Oregon State University College of Pharmacy.

Total
15
Shares
Share 15
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • anti PD-1
  • immune checkpoint blockade (ICB)
  • immunotherapy
  • Lachnospiraceae species
  • melanoma
  • Microbiome
  • Streptococcaceae species
  • transkingdom network analysis
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • News

Starting age for MRI breast screening defined for three genetic mutations

  • 2 March 2022
  • Janet Fricker
View Post
Next Article
  • Articles
  • Delivery of Care

Precision care: supporting our patients starts with asking them what they want and need

  • 4 March 2022
  • Simon Crompton
View Post
You May Also Like
View Post
  • News

Study highlights need to reanalyse genomics and genetics of metastatic tumours

  • Janet Fricker
  • 27 January 2023
View Post
  • News

Current cervical cancer screening paradigm fails older women

  • Janet Fricker
  • 26 January 2023
View Post
  • News

Call-to-arms for Europe to provide essential paediatric anti-cancer medicines

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Exercise-stimulated myokine production can extend survival in advanced prostate cancer

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Five San Antonio take-aways to improve care of breast cancer patients

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Repurposed drug combination reduces risk of recurrence following surgery for colorectal cancer

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Aerobic activity to outcompete metastasis 

  • Janet Fricker
  • 2 December 2022
View Post
  • News

Ending cancer inequalities: European summit showcases new tools to inform policy

  • Anna Wagstaff
  • 30 November 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Study highlights need to reanalyse genomics and genetics of metastatic tumours
    • 27 January 2023
  • Current cervical cancer screening paradigm fails older women
    • 26 January 2023
  • Call-to-arms for Europe to provide essential paediatric anti-cancer medicines
    • 9 January 2023
  • Exercise-stimulated myokine production can extend survival in advanced prostate cancer
    • 9 January 2023
  • Five San Antonio take-aways to improve care of breast cancer patients
    • 16 December 2022
Article
  • The cancer patients still struggling to access drugs in the wake of anti-corruption reforms
    • 27 January 2023
  • Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access
    • 26 January 2023
  • Cervical cancer elimination efforts boosted by simpler ways to identify and treat pre-cancerous lesions
    • 12 January 2023
Latest printed issue
Social

Would you follow us ?

Contents
  • AI in Genomics and Reporting for Clinical Practice
    • 26 January 2023
  • Telemedicine in Cancer Care: Monitoring, Follow-Up,Tele-Rehabilitation, Palliative and Supportive Care
    • 23 January 2023
  • AI application in diagnosis
    • 11 January 2023
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is funded by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.